

Where can I find information on the results of the EVAPORATE trial being presented at the European Society of Cardiology (ESC) Congress 2020- The Digital Experience on Saturday, August 29, 2020?

Final results of the EVAPORATE study are not yet public but have been selected by the European Society of Cardiology (ESC) as a late breaker scientific presentation at the ESC Congress 2020 - The Digital Experience on August 29, 2020 is preliminarily scheduled from 8:50-9:20 am Central European Summer Time (CEST), 2:50-3:20 am Eastern Standard Time (EST). Registration for the ESC conference is free.

To listen to this presentation please visit the Late-Breaking Science in Lipids at

[https://programme.escardio.org/ESC2020/Channels-by-Topic?s=\\${channels\[0\]}=1871&_ga=2.43661548.879190233.1595957224-627377798.1563819807](https://programme.escardio.org/ESC2020/Channels-by-Topic?s=${channels[0]}=1871&_ga=2.43661548.879190233.1595957224-627377798.1563819807)

Amarin cannot provide any additional information on the results or the substance of the schedule presentation per ESC embargo policies.

EVAPORATE is a randomized, double-blind trial of VASCEPA® (icosapent ethyl) 4 g/day compared to placebo in which plaque in patients' arteries was evaluated by coronary computed tomographic angiography (CCTA) scans. Patients underwent a scan at the start of the study, had an interim scan at 9 months, halfway through the study, and were followed for 9 more months with a final CCTA scan at the end of the study. The trial design and interim results were published; these results and other information regarding the trial can be found via this link: [publication](#). More information on the EVAPORATE trial can also be found at <https://clinicaltrials.gov/>.

Dated: July 31, 2020